Affordable Access

deepdyve-link
Publisher Website

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial.

Authors
  • Kishi, Taro1
  • Matsuda, Yuki1
  • Matsunaga, Shinji1
  • Moriwaki, Masatsugu2
  • Otake, Yoichiro3
  • Akamatsu, Kaku4
  • Okochi, Tomo5
  • Hirano, Shigeki5
  • Funahashi, Toshihiko6
  • Okuda, Momoko7
  • Tabuse, Hideaki7
  • Fujita, Kiyoshi3
  • Iwata, Nakao1
  • 1 Department of Psychiatry, Fujita Health University School of Medicine.
  • 2 Department of Psychiatry, Fujita Health University School of Medicine; Department of Psychiatry, Okehazama Hospital, Toyoake.
  • 3 Department of Psychiatry, Okehazama Hospital, Toyoake.
  • 4 Department of Psychiatry, Jindai Clinic, Nagoya.
  • 5 Department of Psychiatry, Toyota Memorial Hospital.
  • 6 Department of Psychiatry, Jindai Hospital, Toyota, Aichi.
  • 7 Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan. , (Japan)
Type
Published Article
Journal
Neuropsychiatric Disease and Treatment
Publisher
Dove Medical Press
Publication Date
Jan 01, 2017
Volume
13
Pages
117–125
Identifiers
DOI: 10.2147/NDT.S124898
PMID: 28123299
Source
Medline
Keywords
License
Unknown

Abstract

Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.

Report this publication

Statistics

Seen <100 times